[email protected]   +1 (304) 306-0723

Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2030

$6,500.00$19,500.00

Growth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2030 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.
The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach $13 billion by 2030.
Clear

Description

Chronic kidney disease (CKD) is a major emerging global public health problem affecting over 94 million people in G7 countries (United States, EU5 and Japan) and over 850 million people and is currently one of the most common diseases in the world. The large number of comorbidities accompanying CKD, the large number of prescribed medications, poor mental health, the high hospitalization rate, and the high mortality rate demonstrate that the patient complexity of CKD is enormous and has exceeded all other medical specialties when nine complexity markers were assessed. Although significant progress has been made in understanding the causes of kidney disease and the factors driving progression to end-stage renal disease, clinical decision support systems that tailor individual patient therapy can reduce the risk of progression and may be used to monitor and modify therapy in individual CKD patients

Chronic Kidney Disease –CKD Epidemiology

The prevalence of all stages of CKD varies between 7–12% in the different regions of the world. CKD (all stages) is most common in people >65 years of age, but the probability of progression to ESRD is higher in younger people (≤65 years of age) with CKD. The CKD associated conditions in the G7 is driven by DD-CKD poised to be 10,35,960 cases by 2030, NDD-CKD (Non-Dialysis CKD) reaching  1,23,65,391 cases by 2030, Anemia reaching 55,31,371 cases by 2030, Hyperphosphatemia expected to reach  10,35,960 cases by 2030 Secondary hyperparathyroidism (SHPT) reaching 4,25,421 cases by 2030, CVD-CKD/DKD Risk Patients reaching 1,32,35,903  by 2030.
Dialysis Patients -(Hemo vs PD)
Dialysis Patients -(Hemo vs PD)- Mellalta Meets
The incidence of kidney failure requiring dialysis or end-stage renal disease (ESRD) transplantation in the United States is among the highest in the world, but it may also be on the decline. In 2017, there were ~500,000 cases on dialysis and will see a steady increase to ~ 550,000 cases by 2030. On July 10, 2019, a presidential executive order launched the Advancing American Kidney Health initiative, establishing a goal of 80% of patients with end-stage renal disease (ESRD) treated with either home dialysis or kidney transplantation by 2025. Subsequently, the Centers for Medicare & Medicaid Services proposed the ESRD Treatment Choices model and described several voluntary models to promote kidney health, home dialysis and kidney transplant.
In the United States, approximately 10% of cases are on peritoneal dialysis and 60% on hemodialysis. With transplantation currently accounting for approximately 30% and home hemodialysis (HD) accounting for 2% of patients, the use of peritoneal dialysis (PD) will need to significantly increase from its current rate of ~ 10% to approach this high goal.

Chronic Kidney Disease–CKD Market Forecast

The Chronic Kidney Disease (CKD) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2019 to $XX billion in 2030, representing 1.1 % annual growth. Primary drivers of this growth will be the uptake of the novel emerging treatment i.e. daprodustat (GlaxoSmithKline), roxadustat(FibroGen/ Astellas Pharma), vadadustat (Mitsubishi Tanabe Pharma/ Otsuka Pharmaceutical/ Akebia Therapeutics) in anemia associated CKD, Tenapanor (Ardelyx) in Hyperphosphatemia associated CKD and and Calcifediol (OpkoHealth) in Secondary hyperparathyroidism (SHPT) associated CKD, Empagliflozin (Boehringer Ingelheim/ Eli Lilly and Company), Dapagliflozin (AstraZeneca) and canagliflozin (Janssen) in CKD-CVD, along with an expanding number of dialysis and non-dialysis CKD cases associated with anemia, hyperphosphatemia, hyperparathyroidism and Cardiovascular Disease (CVD) predominantly in the United States.
Italy Chronic Kidney Disease market Size/ Sales 2030
Italy Chronic Kidney Disease market Size/ Sales 2030- Mellalta Meets

Report Highlights

  • Chronic Kidney Disease–CKD Current Market Trends
  • Chronic Kidney Disease–CKD Current & Forecasted Cases across the G7 Countries
  • Chronic Kidney Disease–CKD Market Opportunities And Sales Potential for Agents
  • Chronic Kidney Disease–CKD Patient-based Market Forecast to 2030
  • Chronic Kidney Disease–CKD Untapped Business Opportunities
  • Chronic Kidney Disease–CKD Product Positioning Vis-a-vis Competitors’ Products
  • Chronic Kidney Disease–CKD KOLs Insight

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • Chronic Kidney Disease Disease Background
    • Chronic Kidney Disease Definition
    • Symptoms
    • Risk Factor
    • Diagnosis
    • Advancing American Kidney Health (AAKH) Initiatives
  • Epidemiology Estimated and Forecast to 2030
    • Epidemiology Research Method & Data Sources Used
      • Prevalent Cases of Chronic Kidney Disease in the United States 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United States 2020-2030
      • Prevalent Cases of Chronic Kidney Disease in Germany 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Germany 2020-2030
      • Prevalent Cases of Chronic Kidney Disease in France 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in France 2020-2030
      • Prevalent Cases of Chronic Kidney Disease in Italy 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Italy 2020-2030
      • Prevalent Cases of Chronic Kidney Disease in Spain 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Spain 2020-2030
      • Prevalent of Chronic Kidney Disease in the United Kingdom 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United Kingdom 2020-2030
      • Prevalent Cases of Chronic Kidney Disease in Japan 2020-2030
      • Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Japan 2020-2030
  • Patients on Dialysis per country
    • Patients on Dialysis per country by Treatment Modality
  • Current Unmet Needs in Chronic Kidney Disease
  • Current Treatment Paradigm
    • Treatment guidelines for Chronic Kidney Disease
    • Current Approved Treatments for CKD
  • Reimbursement Scenario in Chronic Kidney Disease
    • Dialysis modality distribution
    • Global Reimbursement of Different Dialysis Strategies
      • Reimbursement by Self-care hemodialysis, Home hemodialysis, CAPD, APD & Hospital hemodialysis
      • Reimbursement Scenarios in the Belgium, Germany, The Netherlands, United Kingdom, France, United States & Ontario, Canada, Japan and Other countries.
      • Primary Findings
  • Emerging Therapies Chapters
    • daprodustat (GSK)
    • Canagliflozin (J&J/Mitsubishi Tanabe Pharma )
    • darbepoetin alfa (Kissei Pharma/ JCR Pharma)
    • ferumoxytol (AMAG Pharmaceuticals)
    • Roxadustat (FibroGen/ Astellas Pharma)
    • vadadustat (Akebia Therapeutics)
    • Tenapanor (Ardelyx)
    • Bardoxolone methyl (Reata Pharmaceuticals, Inc)
    • Dapagliflozin (AstraZeneca)
    • Empagliflozin (Boehringer Ingelheim/ Eli Lilly)
    • TRC-101 (Tricida Inc.)
    • PDprotec (Zytoprotec)
  • Total Market Forecast
    • Key Summary Findings
      • G7 total Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • G7 total Market for Chronic Kidney Disease by Therapies 2020-2030 (USD Million)
  • Market Forecast by Country
    • United States
      • United States Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • Germany
      • Germany Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • France
      • France Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • Italy
      • Italy Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • Spain
      • Spain Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • United Kingdom
      • United Kingdom Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
    • Japan
      • Japan Market for Chronic Kidney Disease 2020-2030 (USD Million)
      • United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2020-2030 (USD Million)
  • Market Drivers & Barriers
Name
Email
Phone
Enquiry

You may also like…

Get In Touch

Let's keep the conversation going